Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. (Q53716562)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. |
scientific article |
Statements
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. (English)
1 reference
Øyvind S Bruland
1 reference
Sten Nilsson
1 reference
Lars Franzén
1 reference
Christopher Parker
1 reference
Christopher Tyrrell
1 reference
René Blom
1 reference
Jan Tennvall
1 reference
Bo Lennernäs
1 reference
Ulf Petersson
1 reference
Dag C Johannessen
1 reference
Michael Sokal
1 reference
Katharine Pigott
1 reference
Charles Gillies O'Bryan-Tear
1 reference
Marcus Thuresson
1 reference
Bjørg Bolstad
1 reference
26 September 2012
1 reference
11
1 reference
1
1 reference
20-26
1 reference
Identifiers
1 reference